A Pivotal Bioequivalence Study of 250 Mcg NGM/25 Mcg EE [ethinylestradiol/norgestimate] With or Without Folic Acid in Healthy Female Subjects

Trial Profile

A Pivotal Bioequivalence Study of 250 Mcg NGM/25 Mcg EE [ethinylestradiol/norgestimate] With or Without Folic Acid in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2010

At a glance

  • Drugs Ethinylestradiol/norgestimate; Folic acid
  • Indications Menopausal syndrome; Pregnancy
  • Focus Pharmacokinetics; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 28 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top